NASDAQ:NOTV

Inotiv Competitors

$28.71
+0.81 (+2.90 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.42
$30.43
50-Day Range N/A
52-Week Range
$3.90
$30.43
Volume201,708 shs
Average Volume114,750 shs
Market Capitalization$408.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inotiv (NASDAQ:NOTV) Vs. ARQT, AVIR, ESTA, HRTX, AMRX, and REPL

Should you be buying NOTV stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Inotiv, including Arcutis Biotherapeutics (ARQT), Atea Pharmaceuticals (AVIR), Establishment Labs (ESTA), Heron Therapeutics (HRTX), Amneal Pharmaceuticals (AMRX), and Replimune Group (REPL).

Arcutis Biotherapeutics (NASDAQ:ARQT) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arcutis Biotherapeutics and Inotiv, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcutis Biotherapeutics00403.00
Inotiv0000N/A

Arcutis Biotherapeutics currently has a consensus target price of $54.6667, suggesting a potential upside of 67.95%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Inotiv.

Profitability

This table compares Arcutis Biotherapeutics and Inotiv's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcutis BiotherapeuticsN/A-81.74%-57.72%
InotivN/AN/AN/A

Institutional & Insider Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Arcutis Biotherapeutics and Inotiv's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.43
InotivN/AN/AN/AN/AN/A

Summary

Arcutis Biotherapeutics beats Inotiv on 3 of the 5 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Atea Pharmaceuticals and Inotiv, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Inotiv0000N/A

Atea Pharmaceuticals presently has a consensus target price of $69.3333, suggesting a potential upside of 253.20%. Given Atea Pharmaceuticals' higher possible upside, equities analysts clearly believe Atea Pharmaceuticals is more favorable than Inotiv.

Earnings and Valuation

This table compares Atea Pharmaceuticals and Inotiv's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
InotivN/AN/AN/AN/AN/A

Profitability

This table compares Atea Pharmaceuticals and Inotiv's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
InotivN/AN/AN/A

Summary

Atea Pharmaceuticals beats Inotiv on 2 of the 2 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

54.8% of Establishment Labs shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Inotiv and Establishment Labs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inotiv0000N/A
Establishment Labs01302.75

Establishment Labs has a consensus price target of $46.00, suggesting a potential downside of 32.55%. Given Establishment Labs' higher probable upside, analysts plainly believe Establishment Labs is more favorable than Inotiv.

Earnings & Valuation

This table compares Inotiv and Establishment Labs' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InotivN/AN/AN/AN/AN/A
Establishment Labs$89.57 million18.03$-38,150,000.00($1.86)-36.67

Inotiv has higher earnings, but lower revenue than Establishment Labs.

Profitability

This table compares Inotiv and Establishment Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InotivN/AN/AN/A
Establishment Labs-46.40%-49.51%-24.21%

Summary

Establishment Labs beats Inotiv on 5 of the 8 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Inotiv and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InotivN/AN/AN/A
Heron Therapeutics-216.18%-65.06%-49.14%

Analyst Recommendations

This is a breakdown of current recommendations for Inotiv and Heron Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inotiv0000N/A
Heron Therapeutics01402.80

Heron Therapeutics has a consensus target price of $26.00, indicating a potential upside of 48.06%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Inotiv.

Earnings & Valuation

This table compares Inotiv and Heron Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InotivN/AN/AN/AN/AN/A
Heron Therapeutics$145.97 million11.03$-204,750,000.00($2.50)-7.02

Inotiv has higher earnings, but lower revenue than Heron Therapeutics.

Summary

Heron Therapeutics beats Inotiv on 5 of the 8 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Inotiv and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InotivN/AN/AN/A
Amneal Pharmaceuticals3.30%42.02%3.82%

Analyst Recommendations

This is a breakdown of current recommendations for Inotiv and Amneal Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inotiv0000N/A
Amneal Pharmaceuticals01502.83

Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 31.83%. Given Amneal Pharmaceuticals' higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Inotiv.

Earnings & Valuation

This table compares Inotiv and Amneal Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InotivN/AN/AN/AN/AN/A
Amneal Pharmaceuticals$1.63 billion0.98$-361,920,000.00$0.2719.67

Inotiv has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Inotiv on 8 of the 8 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

55.8% of Replimune Group shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Inotiv and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InotivN/AN/AN/A
Replimune GroupN/A-30.23%-24.66%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Inotiv and Replimune Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inotiv0000N/A
Replimune Group00903.00

Replimune Group has a consensus target price of $56.00, indicating a potential upside of 64.75%. Given Replimune Group's higher possible upside, analysts plainly believe Replimune Group is more favorable than Inotiv.

Valuation & Earnings

This table compares Inotiv and Replimune Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InotivN/AN/AN/AN/AN/A
Replimune GroupN/AN/A$-52,630,000.00($1.54)-22.07

Summary

Replimune Group beats Inotiv on 4 of the 6 factors compared between the two stocks.


Inotiv Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$32.55+4.9%$1.63 billionN/A-3.53Gap Up
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.63+8.6%$1.62 billionN/A0.00Upcoming Earnings
Establishment Labs logo
ESTA
Establishment Labs
1.2$68.20+5.0%$1.62 billion$89.57 million-40.35Earnings Announcement
Analyst Revision
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.56+5.3%$1.61 billion$145.97 million-7.11Earnings Announcement
Upcoming Earnings
High Trading Volume
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.31+2.1%$1.59 billion$1.63 billion12.95Earnings Announcement
Analyst Upgrade
Gap Up
Replimune Group logo
REPL
Replimune Group
1.5$33.99+5.4%$1.58 billionN/A-19.20
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$34.83+0.5%$1.56 billionN/A0.00Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.35+0.1%$1.56 billion$392.76 million12.18Earnings Announcement
Analyst Revision
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.48+4.9%$1.55 billion$2.34 million-9.53Earnings Announcement
Analyst Report
BioAtla logo
BCAB
BioAtla
1.7$46.00+1.8%$1.55 billionN/A0.00Gap Down
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$38.62+7.3%$1.55 billionN/A-160.92
Immunovant logo
IMVT
Immunovant
1.6$15.69+6.8%$1.54 billionN/A-12.16Analyst Report
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$43.49+5.4%$1.53 billionN/A0.00
Addus HomeCare logo
ADUS
Addus HomeCare
1.7$96.30+1.0%$1.53 billion$648.79 million0.00
REGENXBIO logo
RGNX
REGENXBIO
1.6$36.00+0.8%$1.53 billion$35.23 million-14.52Earnings Announcement
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$26.80+3.4%$1.52 billionN/A0.00
U.S. Physical Therapy logo
USPH
U.S. Physical Therapy
1.6$118.18+0.8%$1.52 billion$481.97 million50.29Earnings Announcement
Dividend Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
uniQure logo
QURE
uniQure
1.7$32.25+0.9%$1.48 billion$7.28 million-8.55Earnings Announcement
Upcoming Earnings
Inogen logo
INGN
Inogen
1.4$65.35+1.9%$1.46 billion$361.94 million-726.03Earnings Announcement
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.17+3.6%$1.46 billion$102.43 million-16.95Earnings Announcement
Analyst Upgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$65.89+7.4%$1.46 billionN/A-44.52
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$33.83+1.3%$1.46 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$40.70+2.2%$1.44 billionN/A0.00Insider Selling
AlloVir logo
ALVR
AlloVir
1.5$22.03+8.3%$1.43 billionN/A0.00Earnings Announcement
Insider Selling
Analyst Revision
Lantheus logo
LNTH
Lantheus
1.9$21.24+3.4%$1.43 billion$347.34 million265.53Earnings Announcement
Analyst Upgrade
High Trading Volume
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.45+1.2%$1.41 billion$6.20 million-14.23Upcoming Earnings
Kronos Bio logo
KRON
Kronos Bio
1.7$25.06+2.5%$1.41 billionN/A0.00
Eargo logo
EAR
Eargo
1.4$36.67+12.5%$1.40 billionN/A0.00Upcoming Earnings
Pulmonx logo
LUNG
Pulmonx
1.4$39.33+8.2%$1.40 billion$32.60 million0.00High Trading Volume
Bionano Genomics logo
BNGO
Bionano Genomics
1.3$5.01+8.0%$1.40 billion$10.13 million-2.64Upcoming Earnings
Gap Up
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$6.67+2.7%$1.39 billion$4.11 million-4.90Analyst Report
News Coverage
Gap Up
Brookdale Senior Living logo
BKD
Brookdale Senior Living
1.2$7.57+3.3%$1.39 billion$4.06 billion42.06Earnings Announcement
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.41+3.1%$1.38 billion$236.54 million-52.14Earnings Announcement
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$54.78+10.1%$1.37 billion$51.87 million-322.22Analyst Upgrade
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$31.37+9.0%$1.37 billionN/A-10.56Earnings Announcement
Gap Up
Alphatec logo
ATEC
Alphatec
1.0$14.02+7.8%$1.36 billion$113.43 million-12.75Earnings Announcement
Translate Bio logo
TBIO
Translate Bio
1.6$18.00+7.9%$1.35 billion$7.80 million-16.82Analyst Report
Analyst Revision
Zymeworks logo
ZYME
Zymeworks
1.6$28.49+6.4%$1.32 billion$29.54 million-7.56Earnings Announcement
Analyst Revision
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.4$35.77+4.8%$1.31 billionN/A0.00Upcoming Earnings
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.51+12.6%$1.30 billion$82.27 million-15.88Earnings Announcement
News Coverage
Gap Down
Precigen logo
PGEN
Precigen
1.7$6.24+4.8%$1.29 billion$90.72 million-3.32Upcoming Earnings
Insider Selling
News Coverage
908 Devices logo
MASS
908 Devices
1.7$47.18+7.0%$1.29 billionN/A0.00Upcoming Earnings
Alector logo
ALEC
Alector
1.3$16.12+1.4%$1.29 billion$21.22 million-7.23Earnings Announcement
EWTX
Edgewise Therapeutics
1.8$26.95+8.5%$1.28 billionN/A0.00Gap Down
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.5$10.00+1.4%$1.28 billion$320,000.00-6.80Earnings Announcement
Gap Up
Mesa Laboratories logo
MLAB
Mesa Laboratories
1.5$248.80+1.0%$1.28 billion$117.69 million-355.43
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$19.19+2.9%$1.25 billion$73.41 million-4.06Analyst Revision
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$28.62+4.3%$1.25 billionN/A0.00
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$28.29+3.1%$1.24 billion$230,000.00-13.16Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Endo International logo
ENDP
Endo International
1.5$5.28+6.6%$1.23 billion$2.91 billion-7.76Earnings Announcement
Analyst Revision
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.